Can a once-weekly shot protect joints in hemophilia a? new study aims to find out.
NCT ID NCT05181618
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This Phase IV study is testing emicizumab (Hemlibra) in 136 people aged 13 to 70 with moderate or severe hemophilia A who do not have inhibitors. The goal is to see if this drug, given as a shot under the skin, can improve joint health, increase physical activity, and enhance overall well-being compared to their previous treatment. Participants will be followed for up to 36 months, with regular checks on joint status, bleeding rates, and daily activity using a wearable tracker.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Careggi
Florence, Tuscany, 50134, Italy
-
AOU Federico II
Naples, Campania, 80131, Italy
-
Akdeniz Uni School of Medicine
Antalya, 07059, Turkey (Türkiye)
-
Aziza Othmana Hospital
Tunis, Tunisia
-
CHU Farhat Hached
Sousse, 4000, Tunisia
-
Charité Universitätsklinikum Berlin
Berlin, 13353, Germany
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
Ege Uni Medical School
Izmir, 35100, Turkey (Türkiye)
-
Gazi Universitesi Tip Fakultesi
Ankara, 06500, Turkey (Türkiye)
-
Hamilton Health Sciences Corporation
Hamilton, Ontario, L9H 2B7, Canada
-
Hospital Regional Universitario Carlos Haya
Málaga, 29010, Spain
-
Hospital Universitario Vall de Hebron
Barcelona, 08035, Spain
-
Hospital Universitario la Paz
Madrid, 28046, Spain
-
Hospital das Clinicas - UNICAMP
Campinas, São Paulo, 13083-878, Brazil
-
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
Ribeirão Preto, São Paulo, 14051-140, Brazil
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08025, Spain
-
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique
Rabat, 10090, Morocco
-
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, 20122, Italy
-
Istanbul University Cerrahpasa Medical Faculty
Istanbul, 34098, Turkey (Türkiye)
-
Manchester University NHS Foundation Trust (MFT)
Manchester, M13 9WL, United Kingdom
-
Oklahoma Children's Hospital ? Jimmy Everest Center
Oklahoma City, Oklahoma, 73104, United States
-
Orthopaedic Institute for Children
Los Angeles, California, 90007, United States
-
Policlinico Univ. A. Gemelli
Rome, Lazio, 00168, Italy
-
St Thomas Westminster
London, SE1 7EH, United Kingdom
-
University Clinical Centre of Serbia
Belgrade, 11000, Serbia
-
University of Miami Medical Center
Miami, Florida, 33136, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Észak-Pesti Centrumkórház - Honvédkórház
Budapest, 1134, Hungary
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Emicizumab (Hemlibra)
What this could lead to
If successful, this study could show that emicizumab helps protect joints and improves daily life for people with hemophilia A, offering a more convenient treatment option.
What could go wrong
This is an open-label, single-arm study, so results may be biased. It is also a Phase IV trial, meaning the drug is already approved, so the focus is on refining use rather than a breakthrough. Risks include thromboembolic events and injection site reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.